KELLY KOLLMAN: Open Payments
NPI 1710053533 · CHANDLER, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,700 in 79 payments from 20 companies in 2025. Trend: 2023 $945 · 2024 $1,392 · 2025 $1,700
Food & beverage: $1,700
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 20 | $425 |
| Janssen Biotech, Inc. | 10 | $259 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 13 | $171 |
| Lilly USA, LLC | 6 | $151 |
| PFIZER INC. | 5 | $97 |
| Ardelyx, Inc. | 3 | $84 |
| GENZYME CORPORATION | 2 | $72 |
| Ipsen Biopharmaceuticals, Inc | 3 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $65 |
| Madrigal Pharmaceuticals | 2 | $57 |
Products named: TREMFYA, RINVOQ, XIFAXAN, MAVYRET, DUPIXENT, OMVOH, IBSRELA, VELSIPITY.
Industry payments across AZ — which companies pay providers there.
